The most important prognostic factor in carcinoma of the breast is
Which of the following features on mammogram would suggest malignancy?
Gold standard investigation for breast carcinoma screening in a patient with silicone breast implants
Mammography can be best used in?
All of the following are true about mammography except -
Which of the following is the most sensitive investigation for ductal carcinoma in situ (DCIS) of the breast?
What is the next best step for a 22-year-old with a hepatic hemangioma on ultrasound?
Which is not echogenic while doing ultrasonography:
Which of the following ultrasound features of a thyroid nodule is not suggestive of malignancy?
A 45-year-old female presents with a 2 cm thyroid nodule. Which TIRADS category has >95% risk of malignancy?
Explanation: ***Axillary gland involvement*** - The presence and number of involved **axillary lymph nodes** are the single most significant factor in determining prognosis and guiding adjuvant therapy in breast cancer. - Lymphatic spread to the axillary nodes indicates a higher likelihood of distant metastasis, directly impacting survival rates. *Size of tumour* - While **tumor size** is an important prognostic factor and is part of the TNM staging system (T for tumor size), it is less significant than nodal status. - A small tumor with nodal involvement has a worse prognosis than a larger tumor without nodal involvement. *Skin involvement* - **Skin involvement** (T4b in TNM staging) indicates locally advanced disease and is a poor prognostic sign, but it is not as universally important as axillary nodal status in predicting overall survival. - It often reflects aggressive local tumor growth rather than systemic spread as directly as nodal metastasis. *Involvement of muscles* - **Muscle involvement** (specifically the pectoralis major muscle, T4a in TNM staging) signifies locally advanced disease and is associated with a poor prognosis. - Similar to skin involvement, it suggests extensive local spread but is not as strong a predictor of distant metastasis and overall survival as axillary nodal involvement.
Explanation: ***Areas of spiculated microcalcifications*** - **Spiculated microcalcifications** are highly suspicious for malignancy due to their irregular shape, distribution, and association with rapid, uncontrolled cell growth. - These calcifications often represent **necrotic cells** within rapidly growing tumors, which can deposit calcium. *Smooth borders* - **Smooth borders** typically indicate a benign lesion, such as a cyst or fibroadenoma, as they suggest gradual, uniform growth rather than invasive spread. - Malignant lesions tend to have **irregular** or ill-defined borders due to their infiltrative nature. *Well defined lesion* - A **well-defined lesion** usually suggests a benign process, as it indicates a mass that is clearly demarcated from surrounding tissue and is likely encapsulated. - Malignancies, conversely, often exhibit **indistinct or irregular margins** as they invade adjacent structures. *A mass of decreased density* - A mass of **decreased density** is generally considered a benign finding, often representing a **cyst** or an area of normal fatty tissue. - Malignant tumors typically present as a **mass of increased density** due to their cellular proliferation and desmoplastic reaction.
Explanation: ***MRI*** - **MRI** is considered the **gold standard** for breast cancer screening in patients with silicone breast implants due to its superior ability to visualize breast tissue through the implant and detect subtle lesions. - It offers **high sensitivity** in detecting both implant rupture and early malignancies, often providing better clarity than mammography in augmented breasts where implants can obscure tissue. *Mammography* - While a standard screening tool, **mammography** can be limited in patients with silicone implants because the implants can **obscure adjacent breast tissue**, making detection of small masses challenging. - Special views (e.g., **Eklund views**) can be used, but sensitivity is still reduced compared to MRI in augmented breasts. *CT scan* - **CT scans** are not routinely used for primary breast cancer screening due to their use of **ionizing radiation** and lower sensitivity for detecting early breast lesions compared to MRI. - CT is more commonly used for **staging** advanced cancers or evaluating complex masses detected by other modalities. *USG* - **Ultrasound (USG)** is a valuable complementary tool, especially for evaluating palpable lumps or clarifying findings from mammography, but it is **operator-dependent** and has a lower overall sensitivity for general screening compared to MRI. - It is particularly useful for differentiating between **cystic and solid masses** and detecting implant ruptures but is not the gold standard for comprehensive screening in augmented breasts.
Explanation: ***Early breast carcinoma*** - **Mammography** is the gold standard for **early detection of breast carcinoma**, particularly for identifying **microcalcifications** and small masses before they are palpable. - It plays a crucial role in **screening asymptomatic women** to reduce breast cancer mortality. *Mastitis* - **Mastitis** is an **inflammatory condition** of the breast, often associated with infection, which is usually diagnosed clinically. - While mammography might show diffuse **increased density**, it is not the primary diagnostic tool and often has limited value due to inflammatory changes masking pathology. *Fibroadenoma* - **Fibroadenomas** are **benign breast tumors** common in younger women, typically appearing as well-circumscribed masses on mammography. - While mammography can detect them, their characterization often requires **ultrasound** and **biopsy** for definitive diagnosis, as differentiation from malignant lesions can be challenging. *Phylloides tumor* - A **Phylloides tumor** is a rare tumor that can be benign, borderline, or malignant, and it typically presents as a rapidly growing, palpable mass. - Mammography may show a well-defined mass, but **ultrasound** and **core needle biopsy** are essential for accurate diagnosis and distinction from fibroadenomas or malignancy.
Explanation: ***It has a significant radiation risk*** - While mammography involves **ionizing radiation**, the amount for a screening examination is very low, approximating that received from **natural background radiation** over a few weeks. - The benefits of early breast cancer detection significantly outweigh the extremely small theoretical risk of radiation-induced cancer. *It is basically X-ray imaging of the breast* - Mammography uses **low-dose X-rays** to create images of the breast tissue. - This imaging technique is specifically optimized to visualize dense and subtle changes within the breast. *It is a screening tool in breast cancer* - Mammography is a primary and highly effective **screening tool** used to detect breast cancer early, often before palpable lumps develop. - Regular screening significantly reduces breast cancer mortality by allowing for timely diagnosis and intervention. *It can detect microcalcifications* - Mammography is highly sensitive in detecting **microcalcifications**, which are tiny calcium deposits that can sometimes be an early sign of breast cancer, particularly ductal carcinoma in situ (DCIS). - The ability to visualize these small calcifications is crucial for early detection and diagnosis.
Explanation: ***Mammography*** - **Mammography** is the **gold standard** and **primary imaging modality** for detecting **ductal carcinoma in situ (DCIS)**, primarily because it excels at visualizing **microcalcifications**, which are the hallmark of DCIS. - Approximately **80-90% of DCIS cases** present as **microcalcifications** on mammograms, making it the most important screening and diagnostic tool. - Mammography has **high sensitivity (85-95%)** for detecting DCIS, especially calcified forms, and is widely available and cost-effective. *MRI* - While **MRI** has high sensitivity for invasive breast cancer and can detect non-calcified DCIS, it is **not the primary screening tool** for DCIS detection. - MRI is typically used for **staging known DCIS**, evaluating **extent of disease**, detecting **additional foci**, and screening **high-risk patients**. - However, MRI has lower specificity and higher false-positive rates compared to mammography, limiting its use as a primary diagnostic tool. *PET Scan* - **PET scans** are generally **not sensitive** for detecting **DCIS** because DCIS lesions typically have a **low metabolic rate** and do not avidly take up the **FDG tracer**. - PET scans are primarily used for detecting **invasive cancers** and assessing **metastatic disease**, not for non-invasive lesions like DCIS. *Ultrasound* - **Ultrasound** has **limited sensitivity** for detecting **DCIS** because DCIS often does not present as a palpable mass or a distinct sonographic abnormality. - While ultrasound can be useful for evaluating palpable masses or guiding biopsies, it frequently **misses microcalcifications** that are characteristic of DCIS. - Ultrasound is mainly used as a **complementary tool** to mammography, not as a primary diagnostic modality for DCIS.
Explanation: ***MRI*** - **Magnetic Resonance Imaging (MRI)** is the most sensitive and specific imaging modality for confirming the diagnosis of a **hepatic hemangioma** due to its characteristic enhancement patterns. - An MRI with contrast (e.g., gadolinium) can definitively distinguish a hemangioma from other **benign or malignant liver lesions**, especially when the ultrasound findings are equivocal. *Angiography* - **Angiography** is an invasive procedure and is typically reserved for cases where **embolization** or surgical resection of a very large or symptomatic hemangioma is being considered. - It is not the initial diagnostic choice for confirming a suspected hemangioma identified on **ultrasound**. *CT* - A **CT scan** with contrast can also characterize a hemangioma, showing peripheral nodular enhancement followed by progressive centripetal fill-in. - However, **MRI** generally offers superior soft tissue contrast and provides more definitive diagnostic features for hemangiomas, particularly in younger patients where radiation exposure from CT is a concern. *Biopsy* - **Biopsy** of a suspected hepatic hemangioma is generally contraindicated due to the risk of **hemorrhage** and is rarely necessary for diagnosis. - Imaging characteristics (especially on MRI) are usually sufficient to confirm the diagnosis without the need for an invasive procedure.
Explanation: ***Bile*** - Bile is largely composed of **water**, which allows ultrasound waves to pass through it with minimal reflection, appearing **anechoic** (black) on ultrasound. - This property makes the gallbladder lumen, when filled with bile, appear anechoic, which is crucial for identifying structures like gallstones. *Bone* - **Bone** is highly dense and reflects a significant portion of ultrasound waves, making it appear very **echogenic** (bright) on ultrasonography. - Due to its high reflectivity, bone often produces a strong **acoustic shadow** behind it, obscuring deeper structures. *Gas* - **Gas** (air) is a strong reflector of ultrasound waves and appears brightly echogenic, often with a characteristic **dirty shadowing** or **reverberation artifact**. - The presence of gas can significantly hinder visualization of underlying tissues due to its strong reflection and scatter of the ultrasound beam. *Gall stones* - **Gallstones** are solid concretions that are highly reflective of ultrasound waves, appearing as bright, **echogenic foci** within the gallbladder lumen. - A classic ultrasound sign of gallstones is an echogenic structure with strong **posterior acoustic shadowing**.
Explanation: ***Hyperechogenicity*** - A **hyperechoic** thyroid nodule appears brighter than the surrounding parenchyma on ultrasound, typically indicating a benign lesion, such as a **colloid nodule**. - This feature suggests a higher reflection of sound waves, characteristic of tissues rich in **fluid or colloid material**. *Hypoechogenicity* - **Hypoechoic** nodules appear darker than the surrounding thyroid tissue, which is a strong indicator of malignancy due to their often dense cellular structure. - This feature is associated with a higher risk of thyroid cancer and often prompts further investigation with **fine-needle aspiration (FNA)**. *Microcalcification* - The presence of **microcalcifications** (tiny, bright spots) within a thyroid nodule is one of the most specific ultrasound signs of **papillary thyroid carcinoma**. - These calcifications, often punctate, represent psammoma bodies, which are a histopathological hallmark of this common thyroid cancer. *Nonhomogeneous* - A **nonhomogeneous** (heterogeneous) echotexture within a thyroid nodule, characterized by irregular internal architecture, can be suggestive of malignancy. - This often indicates disorganized cellular growth, fibrosis, or cystic degeneration with solid components, which are features seen in various thyroid cancers.
Explanation: ***TIRADS 5*** - A **TIRADS 5** classification indicates a **highly suspicious** nodule with features strongly suggestive of **malignancy**. - This category corresponds to a **>95% risk of malignancy**, necessitating further investigation such as fine-needle aspiration (FNA). *TIRADS 4* - **TIRADS 4** nodules are classified as **moderately suspicious** for malignancy, with a risk ranging from **5% to 50%**. - While requiring follow-up and often FNA, the risk is significantly lower than for TIRADS 5. *TIRADS 2* - **TIRADS 2** nodules are considered **benign**, with a **0% risk of malignancy** (or extremely low). - These nodules typically have features like **spongiform appearance** or purely cystic composition. *TIRADS 3* - **TIRADS 3** nodules are classified as **mildly suspicious**, with a malignancy risk between **0% and 5%**. - They often have some indeterminate features but are predominantly considered to be low risk.
Get full access to all questions, explanations, and performance tracking.
Start For Free